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Abstract
Background Induced hypertension is an established
therapy to treat cerebral vasospasm (CVS) following sub-
arachnoid hemorrhage (SAH) to prevent delayed ischemic
deficits. Currently, there is minimal evidence available
assessing the risk of induced hypertension in the presence
of unsecured aneurysms. The aim of this study was to
investigate the impact of induced hypertension on the
rupturing of unsecured aneurysms in treating CVS.
Methods We conducted a retrospective analysis between
1999 and 2009. Patients with unsecured aneurysms treated
with induced hypertension were identified and stratified as
having (1) additional unruptured unsecured aneurysms or
(2) ruptured unsecured aneurysms. Hemodynamic param-
eters were analyzed and any bleeding recorded.
Results Forty-five patients were included. Of those, 41
had 71 additional unruptured unsecured aneurysms and
four patients had four ruptured unsecured aneurysms. The
mean size of unsecured aneurysms was: 4.0 ± 1.9 mm
(additional unruptured) and 5.3 ± 2.2 mm (ruptured),
respectively. No aneurysm ruptured during therapy. Com-
bining our data with previously published studies, there
appears to be no increase of risk for aneurysm rupture by
induced hypertension when compared to the natural history
(0.5% for group 1, 2.9% for group 2).
Conclusion These data corroborate that induced hyper-
tension may be a safe treatment option to prevent cerebral
infarction in CVS, even in the presence of unsecured
aneurysms. Our findings suggest that induced hypertension
does not increase rupture of unsecured aneurysms. Given
the high risk for cerebral infarction in severe CVS, we
conclude that induced hypertension should not be omitted
due to the presence of unsecured aneurysms.
Keywords Intracranial aneurysm 
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Introduction
In subarachnoid hemorrhage (SAH), securing of the rup-
tured aneurysm is the primary goal of treatment to (1)
prevent rebleeding and (2) treat cerebral vasospasm (CVS)
more aggressively. CVS can be found in up to 70% of
patients angiographically leading to delayed ischemic
neurological deficits (DIND) in 50% of patients with 15 to
20% dying or developing stroke [1–4].
In CVS management, the approach to augment cerebral
perfusion is broadly accepted. Usually this intervention
includes induced arterial hypertension, hypervolemia and
hemodilution, the so called ‘‘triple-H therapy’’, which is
also recommended for the treatment of CVS according to
the guidelines by the Stroke Council of the American Heart
Association (Class IIa recommendation) [5–11].
Induced hypertension appears to be the most relevant
part of therapy [12]. More recently, additional invasive
endovascular methods have been developed to treat
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vasospasm and are being increasingly used, e.g., percuta-
neous transluminal balloon angioplasty (PTA) or the intra-
arterial administration of vasodilating drugs [13–15].
However, arterial hypertension is generally considered a
risk for aneurysm rupture although prospective studies are
still lacking. [5, 11, 16–18] Recently, it was shown that a
history of hypertension multiplies the risk of rupture for
aneurysms smaller than 7 mm [19]. In normotensive
patients, induced hypertension may put considerable
additional stress on the aneurysm wall, thus increasing the
risk of aneurysm rupture.
Still, little is known about the risk of bleeding due to
induced hypertension in the presence of unsecured aneu-
rysms; however, clinicians are often faced with patients
suffering from vasospasm and harboring unsecured aneu-
rysms [20]. This seems even more relevant when
considering the results from the International Study of
Unruptured Intracranial Aneurysms (ISUIA) study that
showed an increased rupture rate, even for small additional
aneurysms, in patients after a previous SAH from another
aneurysm [21].
To date, little evidence is available assessing the risk of
induced hypertension in treating CVS in the presence of
unsecured aneurysms. It was therefore the aim of this ret-
rospective study to evaluate the effects of induced
hypertension after SAH on additional unruptured, unse-
cured aneurysms and ruptured unsecured aneurysms.
Methods
Study Patients
Patients presenting at our neurovascular center between
January 2000 and May 2009 with non-traumatic SAH were
entered in a prospectively conducted database. All patients
receiving induced hypertension due to CVS with at least
one unsecured aneurysm at the onset of induced hyper-
tension were included. The patients meeting these criteria
were identified and the charts reviewed.
Patient Management
After diagnosis of SAH, a four-vessel angiogram was
routinely performed. Hemodynamic target values included
a cerebral perfusion pressure (CPP) greater than 60 mmHg
and the correction of hypovolemia. Aneurysms were
treated by clipping or coiling based on aneurysm charac-
teristics and the clinical condition of the patient. Early
aneurysm treatment (within 24 h) was the goal in all
patients unless the patients were hemodynamically unsta-
ble or moribund. After aneurysm obliteration, all patients
were treated in the neurosurgical intensive care unit
(NICU) and received nimodipine from the day of admission
either orally (6 9 60 mg/day) or intravenously (2 mg/h).
Diagnosis of CVS
Routine surveillance included daily transcranial Doppler
(TCD) measurements. An increase in TCD flow velocity
greater than 150 cm/s was interpreted as Doppler sono-
graphic CVS. In cases of clinical deterioration (new
neurological deficit or a decrease on the Glasgow Coma
Scale), a CT or MRI scan was indicated. In the absence of
structural lesions or hydrocephalus, a delayed neurological
deficit (DIND) due to symptomatic CVS was suspected. In
some poor-grade and ventilated patients, brain tissue pO2
(pti O2) was monitored invasively (Licox, Integra Neu-
rosciences, Plainsboro, NJ, USA) with values below
15 mmHg in tissue oxygenation being interpreted as CVS.
Furthermore, most patients underwent CT or MRI-based
perfusion studies.
In the majority of the patients, angiography was per-
formed and the degree of angiographic vasospasm was
classified into none (0–10%), mild (11–33%), moderate
(34–66%), and severe (67–100%) as described by We-
idauer et al. [22]. Symptomatic vasospasm was defined as
(1) new DIND in the absence of other causes, (2) moderate
or severe angiographic vasospasm or Doppler flow veloc-
ities >150 cm/s and a perfusion deficit on CT- or MRI
perfusion studies or any new infarcts on neuroimaging (CT
or MRI) or (3) moderate or severe angiographic vasospasm
or Doppler flow velocities >150 cm/s and a decrease in pti
O2 < 15 mmHg in tissue oxygen tension.
Induced Hypertension
In cases of symptomatic vasospasm, hypertension was
induced with catecholamines following a stepwise protocol
[12]. The treatment goal was to achieve a CPP of 80 to
120 mmHg corresponding to mean arterial pressure (MAP)
values between 90 and 130 mmHg [23]. Other target
treatment values included normovolemia in the high-nor-
mal range (central venous pressure (CVP) >5 mmHg,
hematocrit (Hc) 0.25 to 0.40). Hypervolemia was not the
primary interest [12]. Systolic blood pressure (SBP,
recorded from an arterial line), vital signs, and hemody-
namic measurements were recorded hourly. Data were
entered into a computerized database from which mean and
maximum SBP, CVP, and MAP values were calculated.
Fluid intake and hemoglobin values were recorded at least
daily.
When conservative therapy failed patients were addi-
tionally treated endovascularly as described elsewhere
[22, 24].
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Statistical Methods
The primary endpoint of the study was defined as the pres-
ence of rupture in any additional unruptured unsecured
aneurysm or ruptured unsecured aneurysm during treatment
with induced hypertension. Secondary outcome measures
included any aneurysm rupture occurring later, after the
treatment with induced hypertension had been finished.
Descriptive analyses were performed for all study vari-
ables. The mean and standard deviation were calculated for
aneurysm diameter. To compare differences between
individuals, a t test was used and P values calculated.
Literature Review
We performed a literature review to evaluate the impact of
induced hypertension on unsecured aneurysms in other
studies. The PubMed database (www.ncbi.nlm.nih.gov/
pubmed) was searched using the keywords ‘‘SAH’’, ‘‘triple
H’’, ‘‘induced hypertension’’, ‘‘unsecured aneurysm’’, and
‘‘hypertensive therapy’’. Only literature published in Eng-
lish until December 2009 was included in this review. The
results were screened for relevance. Copies of the original
papers were retrieved and data extracted when possible.
Furthermore, the references of these papers were reviewed.
Results
Patient Characteristics
Forty-five patients with symptomatic CVS after SAH and
at least one unsecured aneurysm at the onset of induced
hypertension were included. The mean age of patients was
49.4 ± 10.0 years (range: 29–79 years) and 75.6% were
women. All patients presented with SAH due to a ruptured
aneurysm except for one patient who presented with SAH
due to a ruptured dural arterial-venous fistula harboring an
additional unruptured middle cerebral artery (MCA)
aneurysm.
Aneurysm Characteristics
Forty-four patients had a ruptured aneurysm of which 24
were secured by clipping (54.5%) and 16 by coiling
(36.4%). In four patients, the ruptured aneurysm remained
unsecured due to the presence of severe CVS on admission
or poor clinical status. In total, 78 additional unruptured
unsecured aneurysms were present before aneurysm treat-
ment in all 45 patients (Table 1; Fig. 1). In five patients
(no. 17, 25, 27, 34, 38), seven additional aneurysms were
clipped simultaneously when securing the ruptured aneu-
rysm. Finally, at the onset of induced hypertension, 41
patients had 71 additional unruptured, unsecured aneu-
rysms and four patients had four ruptured unsecured
aneurysms.
The mean size of all aneurysms was 5.5 ± 3.6 mm with
the ruptured aneurysms being significantly larger (mean
diameter 8.2 ± 4.3 mm, range: 1–21 mm) than the unrup-
tured ones (mean diameter 4.0 ± 1.9 mm, range: 1–10 mm,
P value < 0.001, t test). The mean size of the four ruptured
unsecured aneurysms was 5.3 ± 2.2 mm (range: 3–8 mm).
Diagnosis of Vasospasm
Cerebral vasospasm was confirmed angiographically in 37
of 45 (82.2%) patients. In four patients (8.9%), diagnosis
was established on the basis of MR-imaging (including
MR-angiography and MR-perfusion) alone, while in
another four patients (8.9%), the diagnosis was based on
TCD and clinical worsening only.
Induced Hypertension
Mean duration of hypertensive therapy was 7.2 days (range
2–13 days) per patient and a total of 310 days for all patients.
During therapy, a mean MAP of 103.01 ± 6.52 mmHg was
achieved corresponding to a mean SBP of 160.89 ± 11.57
mmHg (Table 2). The maximal values were 133.60 ±
13.89 mmHg and 209.65 ± 23.67 mmHg for MAP and
SBP, respectively. Mean CVP was 12.69 ± 2.50 mmHg.
Thirty-five patients received norepinephrine. Of those,
eight patients received a combination of norepinephrine
and dobutamine and 12 patients received a combination of
norepinephrine and dopamine. Two patients were admin-
istered dopamine alone, while in six patients, sufficient
spontaneous hypertension was achieved. Two patients had
missing hemodynamic values and therefore, were excluded
from analyses that included those values.
Volume Management
On average, patients received 545 ± 409 ml hydroxyeth-
ylstarch (HES) 10% per day with a mean total infusion
volume of 6507 ± 1223 ml per day. The overall mean
hemoglobin concentration (n = 45) during the therapy was
10.1 ± 1.1 mg/dl.
Additional Invasive Treatment
Nineteen patients (42.2%) were treated endovascularly. In
one patient, nitroprusside was applied intrathecally and
eight patients underwent decompressive craniectomy due
to brain edema and/or hemispheric infarctions [25, 26]. No
aneurysm rupture occurred in these interventions.
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Table 1 Basic demographic characteristics, location and size of the aneurysms
Nr Age Sex Hunt and
Hess grade
Fisher
grade
Location ruptured
aneurysm
Size
(mm)
Operation Aneurysms
total
Localization and size (mm)
1 44 F 4 3 ICA/Pcom 21 Clipping 2 ICA paraclin. (7)
2 33 F 2 3 ICA-Bif. 3 Clipping 2 BA tip (1)
3 29 F 3 4 AcomA 10 Coiling 3 MCA (3), MCA (2)
4 53 F 5 3 MCA 11 Clipping 4 PICA (7), ICA cav (4), ICA oph (1)
5 36 F 3 3 MCA 9 Clipping 2 MCA (3) cl
6 58 F 3 3 ICA/Pcom 10 Clipping 2 ICA oph (4)
7 36 M 2 3 AcomA 8 n/a 4 M1 (3), ICA chor (3), BA (2, Coiling
unsuccessful)
8 41 F 3 3 ICA opht. 5 Coiling 3 ICA/P (4), ICA cav (6)
9 79 M 4 3 AcomA 6 n/a 1 n/a (Coiling unsuccessful)
10 46 F 3 3 PICA 4 Clipping 3 ICA clin (5), ICA oph (3)
11 49 F 2 3 Acom 6 Clipping 2 pericallosal (6)
12 57 F 4 3 Acom 5 Coiling 3 MCA (2), MCA (3)
13 59 F 4 3 MCA 7 Clipping 4 ICA oph (6), MCA (4), pericallosal (3)
14 35 F 5 3 ICA/Pcom 10 Coiling 2 Acom (2)
15 51 F 2 2 MCA 8 Clipping 3 M2 (4), ICA cav (7)
16 50 F 2 3 ICA/Pcom 6 Clipping 3 ICA/P (5), A1/2 (3)
17 43 M 2 3 MCA 8 Clipping 6 MCA (2, Clip), MCA (2, Clip), MCA (4) cl,
MCA (3) cl, Acom (4)
18 50 F 4 3 Acom 6 Coiling 2 BA (5)
19 54 F 3 3 ICA paracl 17 Coiling 2 ICA oph (4)
20 56 F 2 3 ICA/Pcom 10 Clipping 3 Acom (2), ICA/P (3)
21 46 F 4 3 ICA/Pcom 10 Clipping 2 ICA/P (5)
22 53 M 5 3 MCA 9 Coiling 2 BA (10)
23 45 F 3 4 ICA/Pcom 10 Coiling 3 Acom (4), MCA (2)
24 40 F 2 4 ICA 18 Clipping 3 ICA T (4), MCA (4)
25 43 F 3 3 MCA 8 Clipping 3 MCA (5), Acom (9, Clip)
26 47 F 5 3 MCA 3 Clipping 2 MCA (4)
27 51 F 2 3 BA/SCA 1 Clipping 3 ICA T(4, Clip), BA (1)
28 56 M 1 2 MCA 12 Clipping 2 MCA (5)
29 42 F 3 4 Acom 12 Coiling 2 ICA oph (4)
30 38 F 4 3 MCA 2 Clipping 2 MCA (3)
31 47 M 3 4 MCA 4 n/a 3 MCA (4 and 5)
32 43 F 2 BA 5 Coiling 2 ICA clin (6)
33 58 F 3 3 ICA/Pcom 17 Clipping 2 ICA/P (5)
34 52 M 5 5 ICA/Pcom 7 Clipping 5 MCA (4, Clip), MCA (4), MCA (4) cl,
pericallosal (3)
35 38 F 3 3 BA 3 Coiling 2 MCA (2)
36 69 F 3 3 PICA 7 Coiling 4 MCA (5), MCA (5), MCA (2)
37 52 F 3 2 MCA 8 Clipping 7 ICA cav (5), ACom (2), MCA (8), M1 (2), ICA
oph (10), ICA (3)
38a 62 F 2 1 ICA-Bif. 8 Clipping 4 MCA (5, Clip), A1 (3, Clip), ICA/P (2) cl
39 65 F 5 3 Acom 6 Coiling 2 MCA (5)
40 53 M 4 3 MCA 12 Clipping 2 BA (6)
41 60 M 4 3 A1 3 n/a 2 ICA cav (3)
42 38 M 5 3 A1/A2 8 Coiling 2 MCA (2)
43 52 M 2 3 dAVF n/a Surgery 1 MCA (4)
44 53 F 3 3 Acom 11 Coiling 2 MCA (6)
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Endpoints
When evaluating the primary endpoint, we found that no
aneurysm bled during the period of induced hypertension.
However for the secondary endpoint, one patient had
an unsecured ruptured aneurysm of the anterior
communicating artery (AComA) ruptured 5 days after the
end of induced hypertension. In another patient, who had a
mechanical heart valve requiring continuous anticoagula-
tion, the ruptured aneurysm of the left MCA rebled several
times after clipping: the first rebleeding occurred 2 days
after surgery due to the formation of a pseudoaneurysm
Table 1 continued
Nr Age Sex Hunt and
Hess grade
Fisher
grade
Location ruptured
aneurysm
Size
(mm)
Operation Aneurysms
total
Localization and size (mm)
45 59 F 3 3 ICA/Pcom 8 Coiling 2 MCA (3) cl
Nr patient number, AComA anterior communicating artery, BA basilar artery, bif bifurcation, cl contralateral, dAVF dural arterious-venous-
fistula, ICA internal carotid artery, MCA middle cerebral artery, PCom posterior communicating artery, PICA posterior inferior cerebellar artery,
SCA superior cerebellar artery, oph ophthalmic segment, chor choroidal segment, paraclin paraclinoidal segment
a Diagnosis of SAH via lumbar puncture
Fig. 1 Overall 122 unsecured aneurysms were identified with a
majority of those being additional unruptured, unsecured (78 total)
and predominantly located at the MCA (a) and the largest aneurysms
(mean size) were those ruptured or secured (b). AcomA anterior
communicating artery, ICA paraclin./opht. Paraclinoid segment of the
ICA located on the ophthalmic artery, ICA/Pcom ICA posterior
communicating artery, PICA posterior inferior cerebellar artery
Table 2 Summary of the study participants with additional unruptured unsecured aneurysm or ruptured unsecured aneurysm
Group 1 (unsecured
unruptured aneurysms)
Group 2 (unsecured
ruptured aneurysms)
Total
Number of patients (n) 41 4 45
Number of aneurysms (n) 71 4 122
Mean aneurysm size (mm) 4.0 ± 1.9 5.3 ± 2.2 5.52 ± 3.6
Mean MAP achieved (mmHg) 103.5 98.3 103.0 ± 6.5
Max. MAP achieved (mmHg) 134.0 129.8 133.6 ± 13.9
Aneurysm ruptures 0 0 (2a after treatment period) 0 (during treatment) 2a (after treatment period)
a In one case, an unsecured ruptured aneurysm of the AComA ruptured 5 days after the end of induced hypertension; in the second case, the
patient was on anticoagulants (mechanical heart valve) in which several rebleeds occurred but not during the period of induced hypertension and
the first rebleed occurred 2 days after surgery
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which was then clipped again. Altogether, this patient
suffered five left-sided intraparenchymal rebleedings
always documented by CT. Finally, this patient died due to
intractable intracranial pressure, but the unsecured con-
tralateral MCA aneurysm never had ruptured.
Patient Outcome
Of the 45 patients, 20 (44.4%) made a good recovery
(n = 12 with GOS = 5 [good outcome], n = 8 with
GOS = 4 [moderate disability]) while 25 (55.6%) patients
were dependent or had died (GOS 1–3: n = 12 with GOS 3
[severe disability], n = 4 with GOS = 2 [persistent veg-
etative state], and n = 9 with GOS = 1 [death],
respectively, as described by the Glasgow Outcome Scale).
Discussion
In multiple intracranial aneurysms, securing of all aneu-
rysms is not always feasible or desirable with an
acceptable risk for the patient in the setting of acute SAH.
Our results suggest that aggressive treatment of symp-
tomatic CVS by induced hypertension is safe despite the
presence of unsecured aneurysms (Table 2). As we con-
sidered the risk of DIND and its devastating impact on the
patient’s outcome greater than the risk of another aneu-
rysm rupture, we aimed for CPP values of 80 to
120 mmHg (MAP values between 90 and 130 mmHg) to
treat CVS. In our series, no aneurysm ruptured during the
time the treatment was applied.
In our study, as well as in other series [27], the unrup-
tured aneurysms were significantly smaller than the
ruptured ones. This presents a possible bias indicating that
the risk of aneurysm rupture is related to its size [21, 27].
On the other hand, the ISUIA data demonstrated an
increased risk for small aneurysms independent of their
location for patients who suffered from a previous SAH by
a separate aneurysm [21].
Recently, two studies showed a higher rupture risk for
patients with small aneurysms if they had a history of
hypertension or in the setting of multiple aneurysms [19,
28]. Up to now, few studies investigating ruptured or un-
ruptured aneurysms have been published (Table 3). These
studies tend to have different study objectives making
direct comparison between results difficult. Furthermore,
most studies have been limited to a small number of cases,
while our study appears to be the largest series reported
thus far. Other limitations of the published studies include
(1) the limitation of the maximal SBP to 150, 160 mmHg
or less than a 20% increase in MAP, respectively [29–31],
(2) the general evaluation of the safety of triple-H therapy, T
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and (3) the prophylactic nature of induced hypertension
with lower MAP values (mean 80.2 mmHg) [32].
In three of the reported series, at least one rebleeding
occurred: in the series of Kassell et al. [29], three unse-
cured ruptured aneurysms rebled during hypertensive
therapy (one being fatal, two patients recovering to their
neurological status on admission). In the series of Awad
et al., four out of 14 patients died due to CVS, while only
one patient died because of a re-ruptured aneurysm [31],
emphasizing the higher impact of DIND on the final out-
come compared to treatment-related aneurysm rupture in
CVS. In only one series, a patient with bilateral MCA
aneurysms suffered from the rupture of an additional
unsecured and previously unruptured aneurysm 11 days
after SAH while receiving hypervolemic therapy [33].
Only one series is similar to ours [27]. Hoh et al. reported
that no unsecured, unruptured aneurysm had ruptured due
to induced hypertension in 40 patients. Unfortunately, the
authors only report the maximum 24-h mean SBP and
CVP, while representative mean values for the whole
treatment period are missing.
Overall, including our series, there are now 121 patients
with 187 additional unruptured, unsecured aneurysms
reported who were treated with induced hypertension. Of
these, only one aneurysm (0.83% of patients; 0.54% of
aneurysms) ruptured during therapy [33]. Remarkably,
even ruptured unsecured aneurysms do not seem to rebleed
more often than what is considered a natural occurrence of
rebleeding (1–4% within the first few days and 20–30%
within the first month after SAH) [11]. Including our own
as well as the previously published data, the rupture rate
during therapy corresponds to 11.8%, rising to 17.6% if the
two patients who suffered rebleeding after the treatment
are included as well. This rupture rate is in line with the
aforementioned natural history of these aneurysms. Thus,
individual characteristics of the aneurysm may play a more
important role in its risk of rupture than the short hyper-
tensive period.
The limitations of our study were its retrospective nature
and the limited number of patients. However, no larger or
prospective series have been published so far. Still, the
clinical relevance would warrant further prospective stud-
ies. Furthermore, we cannot answer the question if induced
hypertension is a risk in the long-term rupture risk of
additional aneurysms or the formation of new ones
although it is unlikely that an average of only 7 days of
hypertensive therapy increases that risk.
In summary, induced hypertension during the CVS does
not seem to increase the risk of rupture of intracranial
aneurysms after SAH. This is important for the manage-
ment and clinical decision-making in this group of patients
with a high risk for developing DIND.
Conclusion
The current results and the published data with more than
120 patients reported to date, advocate that treatment of
CVS by induced hypertension should not be omitted
because of the presence of unsecured aneurysms. This
applies to additional unruptured unsecured as well as to
ruptured unsecured aneurysms, however, further large
prospective studies are warranted to prove this.
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